Johnson & Johnson (JNJ) a pharmaceutical, biotechnology, and medical technologies corporation, on Thursday announced positive results from the Phase 3 Vivacity-MG3 study of nipocalimab, an investigational FcRn blocker, in patients with generalized myasthenia gravis or gMG.
The study demonstrated that nipocalimab led to a significant and sustained improvement in disease control over 24 weeks, with a 75% reduction in autoantibody levels.
Notably, the combination of nipocalimab and standard care showed a greater reduction in the MG-ADL score compared to placebo, offering substantial clinical benefit for patients.
Nipocalimab was well-tolerated with a safety profile similar to placebo, with a discontinuation rate of 5.1% compared to 7.1% for placebo.
The results from the Vivacity-MG3 study support the drug's potential as a targeted treatment for gMG, a debilitating autoimmune disease affecting around 700,000 people worldwide.
Johnson & Johnson has submitted a Biologics License Application or BLA to the U.S. FDA and a Marketing Authorisation Application or MAA to the EMA, with the drug receiving U.S. FDA Priority Review for gMG. The data positions nipocalimab as a promising therapeutic option for gMG patients, as it addresses the underlying cause of the disease by reducing harmful autoantibodies.
Currently, JNJ is trading at $146.84 up by 1.06%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.